Evidence map›Paper›PMID 24974947›Full record

ReviewPharmacoepidemiology and drug safety2014

Advantages and problems with pregnancy registries: observations and surprises throughout the life of the International Lamotrigine Pregnancy Registry.

Susan Sinclair, Marianne Cunnington, John Messenheimer, John Weil, Janet Cragan, Richard Lowensohn, Mark Yerby, Patricia Tennis

Open access · greenAbstract readReview
In one paragraph

Review in Pharmacoepidemiology and drug safety, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Observational
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 3 countries.

Susan SinclairUniversity of North Carolina Wilmington, Wilmington, NC, USA; INC Research LLC, Wilmington, NC, USA.
Marianne Cunnington
John Messenheimer
John Weil
Janet Cragan
Richard Lowensohn
Mark Yerby
Patricia Tennis
GlaxoSmithKline (United Kingdom) · GBCenters for Disease Control and Prevention · USOregon Health & Science University · USPacific University Oregon · USResearch Triangle Park Foundation · USRTI International · USUniversity of North Carolina Wilmington · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

purposeThe International Lamotrigine Pregnancy Registry monitored for a signal of a substantial increase in the frequency of major congenital malformations associated with lamotrigine exposures in pregnancy over an 18-year period. Key methodological lessons are discussed.

methodsThe strengths and weaknesses of the Registry were assessed using quantifiable methodological and operational parameters including enrollment, completeness of exposure and outcome data reporting, and lost to follow-up. The choice of comparator groups and stopping rules for registry closure were critically evaluated.

resultsThe reliance on voluntary reporting was associated with a clustered geographical distribution of registered pregnancies. The enrollment rate increased over time with new approvals and indications for lamotrigine and publication of interim data. Reporter burden was minimized through a streamlined data collection approach resulting in a high level of completeness of exposure and primary outcome data. Lost to follow-up rates were high (28.5% overall) representing a major limitation; incentives to increase the completeness of reporting failed to reduce rates. A lack of an internal comparator group complicated data interpretation; but external comparisons with multiple external groups allowed an assessment of consistency of outcome data across multiple data sources. A lack of a priori closure criteria prolonged the life of the Registry, and consideration of regulatory guidelines on this subject is encouraged at the time of conception of future registries.

conclusionsA successful pregnancy exposure registry requires ongoing flexibility and continuous re-assessment of enrollment, recruitment, and retention methods and the availability of comparison data, throughout its lifecycle.

Indexed as

Abnormalities, Drug-InducedAnticonvulsantsFemaleHumansInternational CooperationLamotrigineLost to Follow-UpPharmacoepidemiologyPregnancyRegistriesTriazinesAnticonvulsantsLamotrigineTriazinesbirth defectslamotriginemethodologypharmacoepidemiologypregnancyregistry

Identifiers

PMID24974947
PMCPMC4406353
OpenAlexW2121829472

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.